Business
Publication of a Prospectus
Publication of a Prospectus.
About this update from Astrazeneca Plc
[{"type":"text","content":"\n \nRNS Number : 0175C AstraZeneca PLC 12 June 2019 \n\n12 June 2019 16:45 BST\n \nPublication of Prospectus\n \nFollowing a routine technical update of the Company's Euro Medium Term Note (\"EMTN\") programme established in 2007, the following prospectus has been approved by the UK Listing Authority and is available for viewing:\n \nBase Prospectus for the AstraZeneca PLC U.S. $10,000,000,000 Euro Medium Term Note Programme (the \"Prospectus\").\n \nThe last drawdown under the EMTN programme was in 2016.\n \nTo view the full document, please paste the following URL into the address bar of your browser.\n \nhttp://www.rns-pdf.londonstockexchange.com/rns/0175C_1-2019-6-12.pdf\n \nA copy of the above Prospectus has been submitted to the National Storage Mechanism and will shortly be available for inspection at:\n \nhttp://www.morningstar.co.uk/uk/NSM\n \n \nAbout AstraZeneca\nAstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit astrazeneca.com and follow us on Twitter @AstraZeneca. \n \n\n\n\n\n \nMedia Relations\n\n\n \n\n\n \n\n\n\n\nGonzalo Viña \n\n\n \n\n\n+44 203 749 5916\n\n\n\n\nRob Skelding\n\n\nOncology\n\n\n+44 203 749 5821\n\n\n\n\nRebecca Einhorn\n\n\nOncology\n\n\n+1 301 518 4122\n\n\n\n\nMatt Kent\n\n\nBioPharma\n\n\n+44 203 749 5906\n\n\n\n\nJennifer Hursit\n\n\nOther \n\n\n+44 203 749 5762\n\n\n\n\nChristina Malmberg Hägerstrand\n\n\nSweden\n\n\n+46 8 552 53 106\n\n\n\n\nMichele Meixell\n\n\nUS\n\n\n+1 302 885 2677\n\n\n\n\n \n\n\n \n\n\n \n\n\n\n\nInvestor Relations\n\n\n \n\n\n \n\n\n\n\nThomas Kudsk Larsen\n\n\n \n\n\n+44 203 749 5712\n\n\n\n\nHenry Wheeler\n\n\nOncology\n\n\n+44 203 749 5797\n\n\n\n\nChrister Gruvris\n\n\nBioPharma (cardiovascular; metabolism)\n\n\n+44 203 749 5711\n\n\n\n\nNick Stone\n\n\nBioPharma (respiratory; renal)\n\n\n+44 203 749 5716\n\n\n\n\nJosie Afolabi\n\n\nOther medicines\n\n\n+44 203...